HEALTH OF WOMAN. 2017.8(124):44–50; doi 10.15574/HW.2017.124.44  

Benyuk V. A., Shcherba A. A.
A.A. Bogomolets National Medical University, Kiev

The frequency of bacterial vaginosis (BV) ranges from 12 to 64% among diseases of the female body and in many respects depends on the contingent of the women being examined. Nitrosamines,the metabolic products of obligatory anaerobic bacteria, are coenzymes of carcinogenesis and can be one of the causes of the development of cervical cancer.
The objective: is to evaluate the efficacy of bacterial vaginosis in women of reproductive age.
Patients and methods. Of study 64 women of reproductive age with BV were examined and treated, which 34 patients (group I study) conducted our therapy with tinidazole and the local preparation Lactagel. 30 patients (group II) received standard treatment. The control group consisted of 27 healthy women.
Results. The article presents the results of treatment of BV in women of reproductive age. In 94.1% of cases we’ve achieved a clinically significant effect in compared to Group II (76.7%) after 10 days of treatment. Three months after the end of treatment, recovery occurred in 97.1% of the patients in the main group (Group II – 86.6%).
Conclusions. The application of the complex bacterial vaginosis treatment offered by us showed a high recovery rate and a low rate of relapse in women of reproductive age.
Key words: bacterial vaginosis, diagnosis, treatment, Lactagel.

REFERENCES

1. Beniuk VO, Bu Veivei, Dronova VL, Shcherba OA, Kovaliuk TV. 2016. Suchasni aspekty mikrobnoho peizazhu pikhvy ta humoralnoi imunnoi vidpovidi orhanizmu u zhinok z khlamidiino-virusnym tservikovahinitom, korektsiia porushen. Reproduktyvna endokrynolohiia 6:46–49.

2. Hopchuk OM. 2015. Bakterialnyi vahinoz – terapevtychnyi pohliad na problemu. Zdorove zhenshchіnу 3(99):71–74.

3. Melkumyan AR, Priputnevich TV. 2013. Vlagalischnyie laktobakterii – sovremennyie podhodyi k vidovoy identifikatsii i izucheniyu ih roli v mikrobnom soobschestve. Akusherstvo i ginekologiya 7:18–23.

4. Sidorova IS, Borovkova EI. 2007. Mikroflora polovyih putey u zhenschin reproduktivnogo vozrasta. M, Prakticheskaya meditsina:80.

5. Tuchkina IA, Tysiachka HM. 2013. Bakterialnyi vahinoz yak faktor vysokoho ryzyku porushennia reproduktyvnoho zdorovia v molodomu vitsi. Zdorove zhenshchynу 9(85):110–115.

6. Chernyavskiy VI. 2013. Bakterialnyie bioplenki i infektsii. Annals of Mechnikov Institute 1:86–90.

7. Beyuk VO, Shcherba OA, Lastovetska LD, Bu Weiwei, Vytyshchenko AS. 2017. Modern Technologies of research of a condition of the mucous membrane of the cervix and vagina in patient with mixed infection. Sciences of Europe 14(14);1:70–76.

8. Bradshaw CS, Tabrizi SN, Fairley CK et al. 2006. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J. Infect. Dis. 194(6):828–836. https://doi.org/10.1086/506621; PMid:16941351

9. Pavlova SI, Kilic AO, Kilic SS et al. 2002. Genetic diversity of vaginal lactobacilli from women in different countries based on 16S rRNA gene sequences. J Appl Microbiol. 92:451–459. https://doi.org/10.1046/j.1365-2672.2002.01547.x; PMid:11872120

10. Ravel J, Gajer P, Abdo Z et al. 2011. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. 108;Suppl 1:4680–4687. https://doi.org/10.1073/pnas.1002611107; PMid:20534435 PMCid:PMC3063603

11. Schwebke JR, Desmond R. 2007. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis. 44;2:213–219. https://doi.org/10.1086/509577; PMid:17173219

12. Srinivasan S, Hoffman NG, Morgan MT et al. 2012. Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota 121 to clinical criteria. PLoS One. 7;6:e37818.

13. Srinivasan S, Fredricks DN. 2008. The human vaginal bacterial biota and bacterial vaginosis. Interdiscip Perspect Infect Dis. Vol. 2008. Article ID 750479. https://doi.org/10.1155/2008/750479

14. Thulkar J, Kriplani A, Agarwal N. 2012. A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis. Indian J. Pharmacol. 44(2):243–245. https://doi.org/10.4103/0253-7613.93859; PMid:22529484 PMCid:PMC3326921

15. Turovskiy Y, Noll KS, Chikindas ML. 2011. The etiology of bacterial vaginosis. J Appl Microbiol. 110;5:1105–1128. https://doi.org/10.1111/j.1365-2672.2011.04977.x; PMid:21332897 PMCid:PMC3072448

16. Verstraelen H, Swidsinski A. 2013. The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment. Curr Opin Infect Dis. 26;1:86–89. https://doi.org/10.1097/QCO.0b013e32835c20cd; PMid:23221767